Clinical trial
Aortic Arch Related Cerebral Hazard Trial (ARCH)
NCT00235248 · Assistance Publique - Hôpitaux de Paris, Other · Completed
Key facts
| NCT number | NCT00235248 |
|---|---|
| Title | Aortic Arch Related Cerebral Hazard Trial (ARCH) |
| Official title | Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery |
| Acronym | ARCH |
| Lead sponsor | Assistance Publique - Hôpitaux de Paris, Other |
| Collaborators | National Health and Medical Research Council, Australia Sanofi Industry Bristol-Myers Squibb |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Brain Infarction, Transient Ischemic Attack, Embolism |
| Intervention type | Drug |
| Interventions | Warfarin, Clopidogrel-aspirin |
| Enrollment | 350 |
| Start date | Feb 1, 2002 |
| Primary completion | Dec 1, 2010 |
| Completion | Jul 1, 2012 |
| First posted | Oct 10, 2005 |
| Last update posted | Jul 10, 2012 |
| Countries | Australia, France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: